Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3323 ARTÍCULOS , VIENDO DEL 1591 AL 1605

Coffee and its consumption: benefits and risks

Butt MS, Sultan MT.

Crit Rev Food Sci Nutr. 2011 Apr;51(4):363-73. doi: 10.1080/10408390903586412.

Botulinum toxin type A for Levodopa-induced cervical dyskinesias in Parkinson's disease: unfavorable risk-benefit ratio

Espay AJ, Vaughan JE, Shukla R, Gartner M, Sahay A, Revilla FJ, Duker AP.

Mov Disord. 2011 Apr;26(5):913-4. doi: 10.1002/mds.23522. Epub 2011 Mar 22.

Tinnitus control by dopamine agonist pramipexole in presbycusis patients: a randomized, placebo-controlled, double-blind study

Sziklai I, Szilvássy J, Szilvássy Z.

Laryngoscope. 2011 Apr;121(4):888-93. doi: 10.1002/lary.21461.

[Ladasten in the management of non-motor symptoms of Parkinson's disease]

Sarycheva TN, Rybak VA, Kurushina OV.

Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(1):85-7.

[Parkinsonism due to clebopride]

Berriozabal Diaz L, Zubiaurre Lizarralde L, Castiella Eguzkiza A, Zapata Morcillo E.

Rev Esp Enferm Dig. 2011 Mar;103(3):161-2. doi: 10.4321/s1130-01082011000300014.

PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo

Mairinger S, Erker T, Muller M, Langer O.

Curr Drug Metab. 2011 Oct;12(8):774-92. doi: 10.2174/138920011798356980.

Modulation and absorption of xenobiotics: the synergistic role of CYP450 and P-gp activities in cancer and neurodegenerative disorders

Inglese C, Perrone MG, Berardi F, Perrone R, Colabufo NA.

Curr Drug Metab. 2011 Oct;12(8):702-12. doi: 10.2174/138920011798357015.

Effect of chronic kidney disease on excessive daytime sleepiness in Parkinson disease

Baba Y, Higuchi MA, Fukuyama K, Abe H, Uehara Y, Inoue T, Yamada T.

Eur J Neurol. 2011 Nov;18(11):1299-303. doi: 10.1111/j.1468-1331.2011.03391.x. Epub 2011 Mar 24.

Review of first trial responses in balance control: influence of vestibular loss and Parkinson's disease

Allum JH, Tang KS, Carpenter MG, Oude Nijhuis LB, Bloem BR.

Hum Mov Sci. 2011 Apr;30(2):279-95. doi: 10.1016/j.humov.2010.11.009. Epub 2011 Mar 23.

Reversible dementia and gait disturbance after prolonged use of valproic acid

Evans MD, Shinar R, Yaari R.

Seizure. 2011 Jul;20(6):509-11. doi: 10.1016/j.seizure.2011.02.009. Epub 2011 Mar 23.

Effect of step training and rhythmic auditory stimulation on functional performance in Parkinson patients

Kadivar Z, Corcos DM, Foto J, Hondzinski JM.

Neurorehabil Neural Repair. 2011 Sep;25(7):626-35. doi: 10.1177/1545968311401627. Epub 2011 Mar 24.

Stem cell-based therapies in Parkinson's disease: future hope or current treatment option?

Loewenbrück K, Storch A.

J Neurol. 2011 May;258(Suppl 2):S346-53. doi: 10.1007/s00415-011-5974-4.

Dopaminergic pathway reconstruction by Akt/Rheb-induced axon regeneration

Kim SR, Chen X, Oo TF, Kareva T, Yarygina O, Wang C, During M, Kholodilov N, Burke RE.

Ann Neurol. 2011 Jul;70(1):110-20. doi: 10.1002/ana.22383. Epub 2011 Mar 17.

Determination of minimal clinically important change in early and advanced Parkinson's disease

Hauser RA, Auinger P; Parkinson Study Group.

Mov Disord. 2011 Apr;26(5):813-8. doi: 10.1002/mds.23638. Epub 2011 Mar 24.

Gene-environment interactions: key to unraveling the mystery of Parkinson's disease

Gao HM, Hong JS.

Prog Neurobiol. 2011 Jun;94(1):1-19. doi: 10.1016/j.pneurobio.2011.03.005. Epub 2011 Mar 23.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias